AstraZeneca and Absci Collaborate to Develop AI-powered Cancer Therapeutics
Summary:
AstraZeneca partners with US-based AI biologics firm Absci with the goal to develop new cancer therapeutics. AstraZeneca will invest up to $247 million into R&D, milestone payments, and an upfront fee for Absci. The AI-enabled collaboration focuses on creating innovative antibody treatments for undisclosed types of cancer and refining existing ones. The move underlines the success of AI in enhancing biologic discovery and the diversity of the biologics discovered.
In a breakthrough move, AstraZeneca, the developer of a COVID-19 vaccine, has joined hands with Absci, a US-based biologics company specializing in artificial intelligence. Financial Times reported on December 3 that AstraZeneca is set to invest as much as $247 million on research and development, milestone payments, along with an upfront fee for Absci. The partnership's central goal is the development of a generative AI-based model that will prioritize the creation of innovative antibody therapeutics for treating cancer and refining existing ones. The specific cancer types to be targeted were not identified in the report.
Absci's official website states that its AI technology scans "billions of cells" per week, moving from antibodies to lab-verified candidates in a duration of six weeks. At present, the company is involved in 17 ongoing projects. AstraZeneca's senior vice president, Puja Sapra, voiced that AI is not only enhancing the success rates and speeding up the process of biologics discovery but also enriching the diversity of the biologics discovered.
Absci's CEO, Sean McClain, has validated the collaboration publicly, asserting AstraZeneca's role in augmenting the use of their AI technology, as reported by Reuters. Cointelegraph has reached out to Absci for more details but has yet to receive a response.
AI is set to revolutionize the healthcare sector, offering substantial support to inventive research and data analysis proficiency. In November, Hong Kong’s Hospital Authority announced their test run of an AI model tasked with fighting multidrug-resistant organisms or superbugs by scrutinizing clinical data to ascertain the necessity of prescribing antibiotics, whose excessive use has resulted in the emergence of resilient superbugs in the region.
Published At
12/4/2023 9:42:35 AM
Disclaimer: Algoine does not endorse any content or product on this page. Readers should conduct their own research before taking any actions related to the asset, company, or any information in this article and assume full responsibility for their decisions. This article should not be considered as investment advice. Our news is prepared with AI support.
Do you suspect this content may be misleading, incomplete, or inappropriate in any way, requiring modification or removal?
We appreciate your report.